| ||||
Public Act 099-0320 | ||||
| ||||
| ||||
AN ACT concerning State government.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 5. The Department of Public Health Powers and | ||||
Duties Law of the
Civil Administrative Code of Illinois is | ||||
amended by adding Sections 2310-676 and 2310-677 as follows: | ||||
(20 ILCS 2310/2310-676 new) | ||||
Sec. 2310-676. Advisory council on pediatric autoimmune | ||||
neuropsychiatric disorder associated with streptococcal | ||||
infections and pediatric acute neuropsychiatric syndrome. | ||||
(a) There is established an advisory council on pediatric | ||||
autoimmune neuropsychiatric disorder associated with | ||||
streptococcal infections and pediatric acute neuropsychiatric | ||||
syndrome to advise the Director of Public Health on research, | ||||
diagnosis, treatment, and education relating to the disorder | ||||
and syndrome. | ||||
(b) The advisory council shall consist of the following | ||||
members, who shall be appointed by the Director of Public | ||||
Health within 60 days after the effective date of this | ||||
amendatory Act of the 99th General Assembly: | ||||
(1) An immunologist licensed and practicing in this | ||||
State who has experience treating persons with pediatric | ||||
autoimmune neuropsychiatric disorder associated with |
streptococcal infections and pediatric acute | ||
neuropsychiatric syndrome and the use of intravenous | ||
immunoglobulin. | ||
(2) A health care provider licensed and practicing in | ||
this State who has expertise in treating persons with | ||
pediatric autoimmune neuropsychiatric disorder associated | ||
with streptococcal infections and pediatric acute | ||
neuropsychiatric syndrome and autism. | ||
(3) A representative of PANDAS/PANS Advocacy & | ||
Support. | ||
(4) An osteopathic physician licensed and practicing | ||
in this State who has experience treating persons with | ||
pediatric autoimmune neuropsychiatric disorder associated | ||
with streptococcal infections and pediatric acute | ||
neuropsychiatric syndrome. | ||
(5) A medical researcher with experience conducting | ||
research concerning pediatric autoimmune neuropsychiatric | ||
disorder associated with streptococcal infections, | ||
pediatric acute neuropsychiatric syndrome, | ||
obsessive-compulsive disorder, tic disorder, and other | ||
neurological disorders. | ||
(6) A certified dietitian-nutritionist practicing in | ||
this State who provides services to children with autism | ||
spectrum disorder, attention-deficit hyperactivity | ||
disorder, and other neuro-developmental conditions. | ||
(7) A representative of a professional organization in |
this State for school psychologists. | ||
(8) A child psychiatrist who has experience treating | ||
persons with pediatric autoimmune neuropsychiatric | ||
disorder associated with streptococcal infections and | ||
pediatric acute neuropsychiatric syndrome. | ||
(9) A representative of a professional organization in | ||
this State for school nurses. | ||
(10) A pediatrician who has experience treating | ||
persons with pediatric autoimmune neuropsychiatric | ||
disorder associated with streptococcal infections and | ||
pediatric acute neuropsychiatric syndrome. | ||
(11) A representative of an organization focused on | ||
autism. | ||
(12) A parent with a child who has been diagnosed with | ||
pediatric autoimmune neuropsychiatric disorder associated | ||
with streptococcal infections or pediatric acute | ||
neuropsychiatric syndrome and autism. | ||
(13) A social worker licensed and practicing in this | ||
State. | ||
(14) A representative of the Special Education | ||
Services division of the State Board of Education. | ||
(15) One member of the General Assembly appointed by | ||
the Speaker of the House of Representatives. | ||
(16) One member of the General Assembly appointed by | ||
the President of the Senate. | ||
(17) One member of the General Assembly appointed by |
the Minority Leader of the House of Representatives. | ||
(18) One member of the General Assembly appointed by | ||
the Minority Leader of the Senate. | ||
(c) The Director of Public Health, or his or her designee, | ||
shall be an ex-officio, nonvoting member and shall attend all | ||
meetings of the advisory council. Any member of the advisory | ||
council appointed under this Section may be a member General | ||
Assembly. Members shall receive no compensation for their | ||
services. | ||
(d) The Director of Public Health shall schedule the first | ||
meeting of the advisory council, which shall be held not later | ||
than 90 days after the effective date of this amendatory Act of | ||
the 99th General Assembly. A majority of the council members | ||
shall constitute a quorum. A majority vote of a quorum shall be | ||
required for any official action of the advisory council. The | ||
advisory council shall meet upon the call of the chairperson or | ||
upon the request of a majority of council members. | ||
(e) Not later than January 1, 2017, and annually | ||
thereafter, the advisory council shall issue a report to the | ||
General Assembly with recommendations concerning: | ||
(1) practice guidelines for the diagnosis and | ||
treatment of the disorder and syndrome; | ||
(2) mechanisms to increase clinical awareness and | ||
education regarding the disorder and syndrome among | ||
physicians, including pediatricians, school-based health | ||
centers, and providers of mental health services; |
(3) outreach to educators and parents to increase | ||
awareness of the disorder and syndrome; and | ||
(4) development of a network of volunteer experts on | ||
the diagnosis and treatment of the disorder and syndrome to | ||
assist in education and outreach. | ||
(20 ILCS 2310/2310-677 new) | ||
Sec. 2310-677. Neonatal Abstinence Syndrome Advisory | ||
Committee. | ||
(a) As used in this Section: | ||
"Department" means the Department of Public Health. | ||
"Director" means the Director of Public Health. | ||
"Neonatal Abstinence Syndrome" or "NAS" means various | ||
adverse conditions that occur in a newborn infant who was | ||
exposed to addictive or prescription drugs while in the | ||
mother's womb. | ||
(b) There is created the Advisory Committee on Neonatal | ||
Abstinence Syndrome. The Advisory Committee shall consist of up | ||
to 10 members appointed by the Director of Public Health. The | ||
Director shall make the appointments within 90 days after the | ||
effective date of this amendatory Act of the 99th General | ||
Assembly. Members shall receive no compensation for their | ||
services. The members of the Advisory Committee shall represent | ||
different racial, ethnic, and geographic backgrounds and | ||
consist of: | ||
(1) at least one member representing a statewide |
association of hospitals; | ||
(2) at least one member representing a statewide | ||
organization of pediatricians; | ||
(3) at least one member representing a statewide | ||
organization of obstetricians; | ||
(4) at least one member representing a statewide | ||
organization that advocates for the health of mothers and | ||
infants; | ||
(5) at least one member representing a statewide | ||
organization of licensed physicians; | ||
(6) at least one member who is a licensed practical | ||
nurse, registered professional nurse, or advanced practice | ||
nurse with expertise in the treatment of newborns in | ||
neonatal intensive care units; | ||
(7) at least one member representing a local or | ||
regional public health agency; and | ||
(8) at least one member with expertise in the treatment | ||
of drug dependency and addiction. | ||
(c) In addition to the membership in subsection (a) of this | ||
Section, the following persons or their designees shall serve | ||
as ex officio members of the Advisory Committee: the Director | ||
of Public Health, the Secretary of Human Services, the Director | ||
of Healthcare and Family Services, and the Director of Children | ||
and Family Services. The Director of Public Health, or his or | ||
her designee, shall serve as Chair of the Committee. | ||
(d) The Advisory Committee shall meet at the call of the |
Chair. The Committee shall meet at least 3 times each year and | ||
its initial meeting shall take place within 120 days after the | ||
effective date of this Act. The Advisory Committee shall advise | ||
and assist the Department to: | ||
(1) develop an appropriate standard clinical | ||
definition of "NAS"; | ||
(2) develop a uniform process of identifying NAS; | ||
(3) develop protocols for training hospital personnel | ||
in implementing an appropriate and uniform process for | ||
identifying and treating NAS; | ||
(4) identify and develop options for reporting NAS data | ||
to the Department by using existing or new data reporting | ||
options; and | ||
(5) make recommendations to the Department on | ||
evidence-based guidelines and programs to improve the | ||
outcomes of pregnancies with respect to NAS. | ||
(e) The Advisory Committee shall provide an annual report | ||
of its activities and recommendations to the Director, the | ||
General Assembly, and the Governor by March 31 of each year | ||
beginning in 2016. The final report of the Advisory Committee | ||
shall be submitted by March 31, 2019. | ||
(f) This Section is repealed on June 30, 2019. | ||
Section 99. Effective date. This Act takes effect upon | ||
becoming law.
|